-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 11, Medtech issued an announcement on abnormal fluctuations in stock tradin.
The company's stock closed on August 8, 2022, August 9, 2022, and August 10, 2022 within three consecutive trading day.
The deviation of the price increase from the value has accumulated by more than 20.
The announcement stated that after the company's self-examination, the company's daily operations are normal, the market environment has not undergone major changes, the industry policy, main business, and business model have not undergone major adjustments, the internal production and operation order is normal, and there are no major issues that should be disclosed but not disclose.
informatio.
In terms of major events, including but not limited to major asset reorganizations, share issuances, major transactions, business reorganizations, share repurchases, equity incentives, bankruptcy reorganizations, major business cooperation, and introduction of strategic investors involving listed companie.
On the news, the company announced on the evening of August 5 that on August 4, 2022, the company received the "Notification Letter on Increasing Shares of Suzhou Madison Medical Technology C.
, Lt.
" from M.
Chen Jiansong, the general manager of the compan.
M.
Chen Jiansong, the general manager of the company, plans to increase his shareholding in the company from May 5, 2022 to November 4, 202 The proposed increase in the amount of holdings is not less than RMB 5 million and not more than RMB 10 millio.
This share increase plan No price range is se.
The implementation period of this shareholding plan has passed halfway, and the general manager of the company has a limited time window to increase his holdings of the company's shares, resulting in the company's shareholding has not yet been increase.
Its follow-up will increase its holdings of the company's shares as planne.
On August 10, it was reported that Madison Technology hit the daily limit, and the stock has risen by the daily limit 7 times in the past yea.
As of the close on the 10th of the day, the stock reported 320 yuan, an increase of 102.
On August 11, Medtech rebounded quickly during the session, with an increase of more than 2% within 5 minute.
As of 10:16, it was reported at 289 yuan, with a turnover of 292 million yuan and a turnover rate of 54.
According to the data of the Dragon Tiger List, as non-ST, *ST and S securities, the closing price increase has accumulated by 20% within 3 consecutive trading days, and among the top five companies with a large amount of purchases of Medtech, there are 2 institutions dedicated to i.
seat.
According to statistics, the net amount of institutional seats purchased by Medtech in three trading days was 154253 million yua.
Public information shows that Meditech was born in a period of great changes and transformations in China's medical industr.
It shoulders the mission of improving and enhancing the overall level of China's medical informatizatio.
It is a professional company with clinical information systems and digital operating rooms as its main core busines.
compan.
The company's main business is to provide clinical medical management information system (CIS) series application software and clinical informatization overall solution.
The core self-controllable products are clinical medical management information system (CIS) series application software products and clinical informatization overall solution.
schem.
The 2021 annual report shows that as of December 31, 2021, the company's total operating income was 354 million yuan, a year-on-year increase of 186%; the net profit attributable to shareholders of the parent company was 49534 million yuan, a year-on-year increase of 137%; basic earnings per share was 26 yua.
The company's 2021 annual dividend implementation plan released in June shows that it plans to transfer 3 shares for every 10 shares to all shareholder.
The equity registration date for this equity distribution is June 29, 2022, and the ex-rights and ex-dividend date is June 30, 2022.It is understood that the company has raised funds twice since its listing, with a total of 921 million yuan, and 6 distributions totaling 71 million yuan, with a cumulative fundraising ratio of 71.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
The company's stock closed on August 8, 2022, August 9, 2022, and August 10, 2022 within three consecutive trading day.
The deviation of the price increase from the value has accumulated by more than 20.
The announcement stated that after the company's self-examination, the company's daily operations are normal, the market environment has not undergone major changes, the industry policy, main business, and business model have not undergone major adjustments, the internal production and operation order is normal, and there are no major issues that should be disclosed but not disclose.
informatio.
In terms of major events, including but not limited to major asset reorganizations, share issuances, major transactions, business reorganizations, share repurchases, equity incentives, bankruptcy reorganizations, major business cooperation, and introduction of strategic investors involving listed companie.
On the news, the company announced on the evening of August 5 that on August 4, 2022, the company received the "Notification Letter on Increasing Shares of Suzhou Madison Medical Technology C.
, Lt.
" from M.
Chen Jiansong, the general manager of the compan.
M.
Chen Jiansong, the general manager of the company, plans to increase his shareholding in the company from May 5, 2022 to November 4, 202 The proposed increase in the amount of holdings is not less than RMB 5 million and not more than RMB 10 millio.
This share increase plan No price range is se.
The implementation period of this shareholding plan has passed halfway, and the general manager of the company has a limited time window to increase his holdings of the company's shares, resulting in the company's shareholding has not yet been increase.
Its follow-up will increase its holdings of the company's shares as planne.
On August 10, it was reported that Madison Technology hit the daily limit, and the stock has risen by the daily limit 7 times in the past yea.
As of the close on the 10th of the day, the stock reported 320 yuan, an increase of 102.
On August 11, Medtech rebounded quickly during the session, with an increase of more than 2% within 5 minute.
As of 10:16, it was reported at 289 yuan, with a turnover of 292 million yuan and a turnover rate of 54.
According to the data of the Dragon Tiger List, as non-ST, *ST and S securities, the closing price increase has accumulated by 20% within 3 consecutive trading days, and among the top five companies with a large amount of purchases of Medtech, there are 2 institutions dedicated to i.
seat.
According to statistics, the net amount of institutional seats purchased by Medtech in three trading days was 154253 million yua.
Public information shows that Meditech was born in a period of great changes and transformations in China's medical industr.
It shoulders the mission of improving and enhancing the overall level of China's medical informatizatio.
It is a professional company with clinical information systems and digital operating rooms as its main core busines.
compan.
The company's main business is to provide clinical medical management information system (CIS) series application software and clinical informatization overall solution.
The core self-controllable products are clinical medical management information system (CIS) series application software products and clinical informatization overall solution.
schem.
The 2021 annual report shows that as of December 31, 2021, the company's total operating income was 354 million yuan, a year-on-year increase of 186%; the net profit attributable to shareholders of the parent company was 49534 million yuan, a year-on-year increase of 137%; basic earnings per share was 26 yua.
The company's 2021 annual dividend implementation plan released in June shows that it plans to transfer 3 shares for every 10 shares to all shareholder.
The equity registration date for this equity distribution is June 29, 2022, and the ex-rights and ex-dividend date is June 30, 2022.It is understood that the company has raised funds twice since its listing, with a total of 921 million yuan, and 6 distributions totaling 71 million yuan, with a cumulative fundraising ratio of 71.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
